mRNA Technology Market : Opportunities and Challenges in Latest Research Report for Business Growth| Moderna Therapeutics, BioNTech, Ethris, CureVac, Argos Therapeutics, Sangamo Therapeutics Inc., Pfizer Inc

Global mRNA Technology Market Analysis and Forecast 2020-2030

Market Introduction

The global mRNA technology market is expected to exhibit a marginal growth rate of 1.8% during the forecast period of 2022-2030. One of the major factors driving the market growth is the increased prevalence of medical disorders such as diabetes, tuberculosis (TB), cancer, and cardiovascular diseases (CVDs). The industry is also benefiting from the rising demand for therapeutic drugs and vaccines for COVID-19, Ebola, influenza, infectious and chronic diseases such as HIV, and other viral illnesses. The recent COVID-19 outbreak has been a launching year for the mRNA technology platforms with the extensive use of mRNA vaccines for treating COVID-19. The market has observed skyrocketed sales of COVID-19 mRNA vaccines during 2020 and 2021. Moreover, the fact that mRNA vaccines hold much more potential than current prophylactic COVID-19 vaccines coupled with the soaring investments in the development of mRNA-based technologies and the perception that COVID-19 will continue to affect the global population, the market for mRNA technologies is expected to witness a steady decline in the few upcoming years.

Request Sample Copy @ https://www.themarketinsights.com/request-sample/265166

Market Segmentation

The rise in the prevalence of cancer is expected to provide significant growth opportunities for the market during the forecast period. For instance, according to the World Health Organization (WHO), cancer is one of the leading causes of mortalities globally which accounted for around 10 million mortalities in 2020. Cancer-causing infections such as hepatitis and human papillomavirus are responsible for 30% of cancer cases in low and lower-middle-income countries. Moreover in 2021, according to the National Center for Health Statistics, 1,896,180 new cases cancer cases and 608,570 cancer mortalities were recorded in the US.

Check for Discount @ https://www.themarketinsights.com/check-discount/265166

Market Structure and Competitive Landscape

The global mRNA technology market is competitive and consists of a number of global and regional players operating in the market. Pharmaceutical companies are investing in mRNA technology as it allows them to mix numerous molecules into a therapeutic drug, which is another important growth factor. The major companies in the market include
Moderna Therapeutics,
BioNTech,
Ethris,
CureVac,
Argos Therapeutics,
Sangamo Therapeutics Inc.,
Pfizer Inc,
Biocon,
Tiba Biotechnology,
Verve Therapeutics Ltd.
and many more. Diversified portfolios of leading firms in innovations and R&D activities characterize the global market, and they are likely to prioritize mergers and acquisitions, and collaborations. Recent developments observed in the market include,
In June 2022, Pfizer Inc. announced to invest US$ 120 million in its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir tablets and ritonavir tablets).
In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring, and painful disease. The collaboration builds on the companies success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.

Report Customization available as per requirements @ https://www.themarketinsights.com/request-customization/265166

Table of Content

Chapter One: Market Introduction
1.1. Scope of Study
1.2. Problem Statement
1.3. Market Segmentation
Chapter Two: Assumptions and Acronyms
Chapter Three: Executive Summary
3.1. Global Market in2022
3.2. Analyst Insights & Recommendations
3.3. Growth Opportunities and Key Strategies
3.4. Supply-side and Demand-side Trends
Chapter Four: Research Methodology
Chapter Five: Analysis of COVID-19 Impact and Road Ahead
5.1. Impact on Growth Strategies
5.2. Impact on Operations and Supply Chain
5.3. Impact on Roll-outs Plans
Chapter Six: Market Indicators and Background
6.1. Macro-Economic Factors
6.2. Forecasting Factors
Robust assessment of various factors including industrial performance, industry players expenditures, and economic conditions, among others
6.3. Supply Chain & Value Chain Analysis
6.3.1. mRNA Technology Providers
6.3.2. Key End User
6.4. Industry SWOT Analysis
6.5. PESTLE Analysis
6.6. Porter s Five Forces Analysis
Chapter Seven: Rules & Regulations
Chapter Eight: Global and Regional Market Dynamics
8.1. Drivers
8.2. Restraints
8.3. Trends
8.4. Opportunities
Chapter Nine: Global mRNA Technology Industry: Key Investment and Development Analysis
9.1. By Leading Providers
9.2. By Region
9.3. By Product
9.4. By Application
9.5. M&A Activities
Robust assessment of major investments made by various industry players along with key application areas, and key regions
Chapter Ten: Market Spending & Use Case Analysis
Chapter Eleven: Product/Drug Pipeline Analysis
11.1. By Key Players
11.2. By Product
11.3. By Application
11.4. By Region
Chapter Twelve: Clinical Trials Analysis
Exhaustive list of all the clinical trials sponsored by various industry players based on the technology will be provided. Moreover, it would also categorize the trials into IND submissions, Phase I, Phase II etc.
Chapter Thirteen: Parent Market Overview: Global Healthcare & Life Sciences Market
Chapter Fourteen: Segmental Analysis
14.1. Global mRNA Technology Market by Product
14.1.1. Segment Overview
14.1.1.1. Prophylactic Vaccines
14.1.1.2. Therapeutic Vaccines
14.1.1.3. Therapeutics
14.2. Global mRNA Technology Market by Manufacturing
14.2.1. Segment Overview
14.2.1.1. In-House
14.2.1.2. Outsourced
14.3. Global mRNA Technology Market by Application
14.3.1. Segmental Overview
14.3.1.1. Oncology
14.3.1.2. Respiratory Diseases
14.3.1.3. Infectious Diseases
14.3.1.4. Rare Diseases
14.3.1.5. Others (Coronary Artery Diseases etc. )
14.4. Global mRNA Technology Market by End User
14.4.1. Segment Overview
14.4.1.1. Hospitals and Clinics
14.4.1.2. Academic & Research Institutions
14.5. Global mRNA Technology Market by Region
14.5.1. Segment Overview
14.5.1.1. North America
14.5.1.2. Latin America
14.5.1.3. Western Europe
14.5.1.4. Eastern Europe
14.5.1.5. Asia Pacific
14.5.1.6. Middle East & Africa
Chapter Fifteen: Regional Analysis
15.1. North America mRNA Technology Market Analysis and Forecast2020-2030
15.1.1. Regional Market Overview and Key Takeaways
15.1.2. North America mRNA Technology Market by Product
15.1.3. North America mRNA Technology Market by Manufacturing
15.1.4. North America mRNA Technology Market by Application
15.1.5. North America mRNA Technology Market by End User
15.1.6. North America mRNA Technology Market by Country
15.1.6.1. US
15.1.6.2. Canada
15.2. Latin America mRNA Technology Market Analysis and Forecast2020-2030
15.2.1. Regional Market Overview and Key Takeaways
15.2.2. Latin America mRNA Technology Market by Product
15.2.3. Latin America mRNA Technology Market by Manufacturing
15.2.4. Latin America mRNA Technology Market by Application
15.2.5. Latin America mRNA Technology Market by End User
15.2.6. Latin America mRNA Technology Market by Country
15.2.6.1. Brazil
15.2.6.2. Mexico
15.2.6.3. Rest of Latin America
15.3. Western Europe mRNA Technology Market Analysis and Forecast2020-2030
15.3.1. Regional Market Overview and Key Takeaways
15.3.2. Western Europe mRNA Technology Market by Product
15.3.3. Western Europe mRNA Technology Market by Manufacturing
15.3.4. Western Europe mRNA Technology Market by Application
15.3.5. Western Europe mRNA Technology Market by End User
15.3.6. Western Europe mRNA Technology Market by Country
15.3.6.1. Germany
15.3.6.2. UK
15.3.6.3. France
15.3.6.4. Spain
15.3.6.5. Italy
15.3.6.6. Benelux
15.3.6.7. Nordic
15.3.6.8. Rest of Western Europe
15.4. Eastern Europe mRNA Technology Market Analysis and Forecast2020-2030
15.4.1. Regional Market Overview and Key Takeaways
15.4.2. Eastern Europe mRNA Technology Market by Product
15.4.3. Eastern Europe mRNA Technology Market by Manufacturing
15.4.4. Eastern Europe mRNA Technology Market by Application
15.4.5. Eastern Europe mRNA Technology Market by End User
15.4.6. Eastern Europe mRNA Technology Market by Country
15.4.6.1. Russia
15.4.6.2. Poland
15.4.6.3. Rest of Eastern Europe
15.5. Asia Pacific mRNA Technology Market Analysis and Forecast2020-2030
15.5.1. Regional Market Overview and Key Takeaways
15.5.2. Asia Pacific mRNA Technology Market by Product
15.5.3. Asia Pacific mRNA Technology Market by Manufacturing
15.5.4. Asia Pacific mRNA Technology Market by Application
15.5.5. Asia Pacific mRNA Technology Market by End User
15.5.6. Asia Pacific mRNA Technology Market by Country
15.5.6.1. China
15.5.6.2. Japan
15.5.6.3. India
15.5.6.4. South Korea
15.5.6.5. Australia
15.5.6.6. ASEAN
15.5.6.7. Rest of Asia-Pacific
15.6. Middle East & Africa mRNA Technology Market Analysis and Forecast2020-2030
15.6.1. Regional Market Overview and Key Takeaways
15.6.2. Middle East & Africa mRNA Technology Market by Product
15.6.3. Middle East & Africa mRNA Technology Market by Manufacturing
15.6.4. Middle East & Africa mRNA Technology Market by Application
15.6.5. Middle East & Africa mRNA Technology Market by End User
15.6.6. Middle East & Africa mRNA Technology Market by Country
15.6.6.1. GCC
15.6.6.2. South Africa
15.6.6.3. Turkey
15.6.6.4. Rest of the Middle East & Africa
Chapter Sixteen: Competitive Landscape
16.1. Competition Dashboard
16.1.1. Global and Regional Market Share Analysis
16.1.2. Market Structure
16.2. Competitive Benchmarking
16.3. Key Strategy Analysis
16.4. Company Profiles
16.4.1. Moderna Therapeutics
16.4.1.1. Company Overview
16.4.1.2. Product/Service Offerings
16.4.1.3. Key Financials
16.4.1.4. Recent Developments
16.4.2. BioNTech SE
16.4.2.1. Company Overview
16.4.2.2. Product/Service Offerings
16.4.2.3. Key Financials
16.4.2.4. Recent Developments
16.4.3. Ethris GmbH
16.4.3.1. Company Overview
16.4.3.2. Product/Service Offerings
16.4.3.3. Key Financials
16.4.3.4. Recent Developments
16.4.4. AstraZeneca Plc
16.4.4.1. Company Overview
16.4.4.2. Product/Service Offerings
16.4.4.3. Financials
16.4.4.4. Recent Developments
16.4.5. CureVac AG
16.4.5.1. Company Overview
16.4.5.2. Product/Service Offerings
16.4.5.3. Financials
16.4.5.4. Recent Developments
16.4.6. Argos Therapeutics, Inc.
16.4.6.1. Company Overview
16.4.6.2. Product/Service Offerings
16.4.6.3. Financials
16.4.6.4. Recent Developments
16.4.7. Sangamo Therapeutics Inc.
16.4.7.1. Company Overview
16.4.7.2. Product/Service Offerings
16.4.7.3. Financials
16.4.7.4. Recent Developments
16.4.8. Pfizer Inc.
16.4.8.1. Company Overview
16.4.8.2. Product/Service Offerings
16.4.8.3. Financials
16.4.8.4. Recent Developments
16.4.9. Biocon Ltd.
16.4.9.1. Company Overview
16.4.9.2. Product/Service Offerings
16.4.9.3. Financials
16.4.9.4. Recent Developments
16.4.10. Tiba Biotechnology
16.4.10.1. Company Overview
16.4.10.2. Product/Service Offerings
16.4.10.3. Financials
16.4.10.4. Recent Developments
16.4.11. Verve Therapeutics Inc.
16.4.11.1. Company Overview
16.4.11.2. Product/Service Offerings
16.4.11.3. Financials
16.4.11.4. Recent Developments
16.4.12. Takeda Pharmaceutical Co, Ltd.
16.4.12.1. Company Overview
16.4.12.2. Product/Service Offerings
16.4.12.3. Financials
16.4.12.4. Recent Developments
16.4.13. Intellia Therapeutics Inc.
16.4.13.1. Company Overview
16.4.13.2. Product/Service Offerings
16.4.13.3. Financials
16.4.13.4. Recent Developments
16.4.14. Kernal Biologics Inc.
16.4.14.1. Company Overview
16.4.14.2. Product/Service Offerings
16.4.14.3. Financials
16.4.14.4. Recent Developments
*List not exhaustive (Players can be added or replaced as per the customization)
Chapter Seventeen: Disclaimer

Direct Contact
Jessica Joyal
+1(213)338-8279 | +1(877)376-9989
sales@themarketinsights.com

About us.
Delivering foresights along with statistical analysis of the operational business industry impacts has been our foremost priority. With the constant developments in the research & development industry, we have always challenged the conventional research methodologies and discovered new research tactics to evolve the growing B2B requirements.

This release was published on openPR.